MMT is out to lunch

Discussion in 'Magnolia Medical Technologies' started by Salesforce Analyst, Nov 19, 2017 at 12:55 PM.

Tags: Add Tags
  1. The VP of Sales & CCO are a total joke, and have no clue on how to get this product to become standard of care.
    Way to complex and way overpriced.
     

  2. anonymous

    anonymous Guest

    None of that matters, what matters is that Steripath is never going to become standard of care, and the company will go out of business in the next six months. All of those large egos will be on the unemployment line. The lower priced more simplistic blood culture reduction company will go on to become the standard of care. Hospitals aren't interested in what Magnolia is selling.
     
  3. anonymous

    anonymous Guest

    Did everyone see the lawsuit that Kurin just brought against Magnolia?
    Magnolia is finished.

    LMAO
     
  4. anonymous

    anonymous Guest

    Wow someone works for Kurin.... L2 not be so obvious techno not savvy jackass
     
  5. anonymous

    anonymous Guest

    Sounds like Magnolia is just blowing investor seed money and that they are not becoming the standard of care in blood culture contamination.
    Losers!